Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Bharat Biotech has a history of successful vaccine commercialization in South Asia. Sign up below to get this incredible offer! MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. The potential synergies of such a union do not seem clear. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. It means that raising capital will be more difficult going forward. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Type a symbol or company name. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Type a symbol or company name. The FDA's decision not to issue EUA really wasn't all that surprising, though. These symbols will be available throughout the site during your session. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Do Not Sell My Personal Information (CA Residents Only). Nasdaq 2023 InvestorPlace Media, LLC. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Keith Speights has no position in any of the stocks mentioned. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. The Motley Fool has a disclosure policy. At the time, Ocugen was left for dead. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Written by Copyright 2023 InvestorPlace Media, LLC. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. Investors need to understand the risk profile here. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Copy and paste multiple symbols separated by spaces. You canfollow Will on Twitterat @HealyWriting. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. Conditions have only become worse since that time. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. But it does mean something. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. The Motley Fool recommends Moderna Inc. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. How long might it take for Ocugen to win full FDA approval for Covaxin? But just because a company does not have crippling debt doesnt mean its a buy. *Stock Advisor returns as of June 7, 2021. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The company initiated its Phase 3 trial of OCU300 back in July 2018. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Thats the thing with these low-priced penny stocks. Most biotech companies have intriguing stories on paper; Ocugen is no different. Theres even room for more lines. However, I wont be around to find out. This requires no immediate effort on your part. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. 1125 N. Charles St, Baltimore, MD 21201. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. The Ocugen deal is a way to salvage some limited value. See disclosure here. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Guys, theres no revenue here! Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. But if they do, Ocugen stock at the least looks like an intriguing bet. So, what goes wrong? Even at around 40 cents per share, I would consider Ocugen stock overvalued. Theres an opportunity here. Investors should worry about companies with no revenue even under the best of circumstances. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. First, the balance sheet is in at least decent shape. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. That's right -- they think these 10 stocks are even better buys. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Create your Watchlist to save your favorite quotes on Nasdaq.com. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. Type a symbol or company name. How can we possibly evaluate a stock on a fundamental basis with that being reality? Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. Custom BMW. Ill be sticking to the stocks that are actually working. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. market." 7 Travel Stocks to Buy Banking On Pent-Up Demand. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. The average Ocugen stock price for the last 52 weeks is 2.10. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. Like other life sciences companies involved in Covid-19 vaccine. Accordingly, the analyst rates OCGN a Neutral (i.e. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. These options will be cheaper than owning the stock itself. Unfortunately for longs, OCGN is much closer to the worst of conditions. If they invent a miracle treatment for a condition, the money will find its way to the stock. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Please check your download folder. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. Maybe OCGN stock will be one of them again. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. This decision. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Investors were hopeful that the small drugmaker would be able to win U.S. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. There's still a chance that the vaccine could receive a green light in Canada. Ocugen isnt a promotional, fly-by-night penny stock. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). The Motley Fool->. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. A $30 million market capitalization doesnt mean Ocugen has no chance. If OCU300 is approved, theres a reasonably large market. Emergency Use . For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Do not expect a recovery in Ocugen stock. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Theres even room for more lines. If Ocugen goes up, you can still profit. Other than an emphasis on cell therapies, the companies had almost nothing in common. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. However, when that occurred, Ocugen stock lost most of its value. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. To make the world smarter, happier, and richer. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. As of this writing, Vince Martin has no positions in any securities mentioned. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. The biotech stock promptly crashed by more than 30%. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. All rights reserved. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. Its worth emphasizing: Ocugen stock is a play with enormous risk. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Investing is always a game of balancing risk and reward. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. For now, though, what happens in India stays in India. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. It has real management. At the beginning of 2020, Ocugen shares were trading at just 47 cents. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. The statistics support having long-term exposure to this asset class. Start trading Options with Saxo today. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. I will concede this: The one great thing about the stock market is there is a style for everyone. That doesnt mean success is guaranteed. Typically, I care little about financials with biotechs. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. While anything is possible, I would not anticipate a miracle here. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. Can you feel the ground moving beneath your feet? Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. The $25 million private placement executed before the merger brought in much-needed cash. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. For priority reviews, the timeline for an approval decision is reduced to six months. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. Even before that point, the most promising candidates generally can find funding. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. But there is no question some big-name stocks performed better than others along the way. Plus500. Making the world smarter, happier, and richer. Cost basis and return based on previous market day close. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity.